Popular terms

[SEARCH]

G Proteins topics
G Proteins
Antibodies
Immunoglobulin
Metalloprotein
Chemotherapeutic Agent
Kinase Inhibitor
Tetrapeptide
Apoptosis Protein
Topoisomerase
Peptidomimetic
Fractionation
Medical Treatment
Chromatograph
Encapsulation
Electrospraying

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

G Proteins patents



      
           
This page is updated frequently with new G Proteins-related patent applications. Subscribe to the G Proteins RSS feed to automatically get the update: related G RSS feeds. RSS updates for this page: G Proteins RSS RSS


Cholate and deoxycholate-based amphiphiles for membrane protein manipulation

Agilent Technologies

Microfluidic glycan analysis


Date/App# patent app List of recent G Proteins-related patents
07/23/15
20150203592 
 Compositions and methods for treating osteoarthritis patent thumbnailCompositions and methods for treating osteoarthritis
The present invention relates to the treatment of osteoarthritis in a human subject using anti-il-1α and anti-il-1β dvd-ig proteins. In various embodiments, the osteoarthritis includes knee osteoarthritis or hand osteoarthritis..
Abbvie Inc.


07/23/15
20150203591 
 Mutivalent antigen-binding proteins patent thumbnailMutivalent antigen-binding proteins
Multivalent antigen-binding proteins comprising two or three or four or more immunoglobulin heavy chain variable domain binding domains are provided, as are methods for making them, nucleic acid constructs, and cell lines for making them. Proteins comprising two or three or four or more different heavy chain variable domains that lack an immunoglobulin variable domain are provided.
Regeneron Pharmaceuticals, Inc.


07/23/15
20150203441 
 Cholate and deoxycholate-based amphiphiles for membrane protein manipulation patent thumbnailCholate and deoxycholate-based amphiphiles for membrane protein manipulation
Disclosed are compounds and methods for manipulating proteins in general and membrane proteins in particular. The compounds can be prepared from cholic acid, deoxycholic acid, lithocholic acid, or derivatives thereof.
Wisconsin Alumni Research Foundation


07/16/15
20150198611 
 Microfluidic glycan analysis patent thumbnailMicrofluidic glycan analysis
Microfluidic devices and methods for analyzing glycan profiles of glycoproteins are provided. Some embodiments of the devices comprise a deglycosylation column for cleaving glycans, an optional cleaning column for removing proteins, a trapping column for enriching glycans, and a separation column for resolving glycans.
Agilent Technologies, Inc.


07/16/15
20150198605 
 Use of antibody-surrogate antigen systems for detection of analytes patent thumbnailUse of antibody-surrogate antigen systems for detection of analytes
Compositions, methods and kits for labeling proteins and uses in reporter systems for detecting, quantifying and/or characterizing analytes.. .
Applied Biosystems, Llc


07/16/15
20150197780 
 Methods for enhancing the degradation of cellulosic material with chitin binding proteins patent thumbnailMethods for enhancing the degradation of cellulosic material with chitin binding proteins
The present invention relates to methods for degrading or converting a cellulosic material and for producing substances from the cellulosic material.. .
Novozymes, Inc.


07/16/15
20150196684 
 Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation patent thumbnailPolysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation
Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent.
Allergan, Inc.


07/09/15
20150191537 
 Antibodies specific for sclerostin and methods for increasing bone mineralization patent thumbnailAntibodies specific for sclerostin and methods for increasing bone mineralization
Compositions and methods relating to antibodies that specifically bind to tgf-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a tgf-beta binding protein sclerostin and a tgf-beta superfamily member, particularly a bone morphogenic protein.
Ucb Pharma S.a.


07/02/15
20150183867 
 Dual variable domain immunoglobulins and uses thereof patent thumbnailDual variable domain immunoglobulins and uses thereof
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie Inc.


07/02/15
20150182617 
 Glycoproteins for pseudotyping lentivectors patent thumbnailGlycoproteins for pseudotyping lentivectors
The invention relates to compositions and methods based on the use of viral g proteins to pseudotype vectors. The viral g proteins can be expressed by expression vectors and can be used to pseudotype lentiviral vectors.
Theravectys


07/02/15
20150182599 

Surfactant protein d for the treatment of disorders associated with lung injury


Surfactant protein d (sp-d) is a 43-kda member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (bpd) using recombinant human surfactant protein d and surfactant formulations..
Children's Hospital Medical Center


06/25/15
20150176002 

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


06/25/15
20150174265 

Reversible masking of pore-forming proteins for macromolecular delivery


The present invention features compositions and methods for enhancing endosomal escape of therapeutic agents in the cytoplasm of a cell to thereby provide more effective therapy. The endocytic pathway is the major uptake mechanism of cells, and biological agents such as proteins, dna, and sirna become entrapped in endosomes and subsequently degraded by lysosomal enzymes.
Massachusetts Institute Of Technology


06/25/15
20150174198 

Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus or dna virus spike protein


The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with f and hn, which are envelope glycoproteins of sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis.
Dnavec Corporation


06/25/15
20150173332 

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


06/25/15
20150173331 

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


06/18/15
20150167019 

Methods and products for transfecting cells


The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using rna are disclosed.
Factor Bioscience Inc.


06/18/15
20150166985 

Methods for correcting von willebrand factor point mutations


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a mutant von willebrand factor protein to correct a point mutation associated with a disease or disorder, e.g., with von willebrand disease. The methods provided are useful for correcting a vwf point mutation within the genome of a cell or subject, e.g., within the human genome.
President And Fellows Of Harvard College


06/18/15
20150166984 

Methods for correcting alpha-antitrypsin point mutations


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a mutant α-antitrypsin protein to correct a point mutation associated with a disease or disorder, e.g., with chronic obstructive pulmonary disease (copd) disease. The methods provided are useful for correcting an α-antitrypsin point mutation within the genome of a cell or subject, e.g., within the human genome.
President And Fellows Of Harvard College


06/18/15
20150166983 

Methods for correcting presenilin point mutations


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a mutant presenilin1 protein to correct a point mutation associated with a disease or disorder, e.g., with familial alzheimer's disease. The methods provided are useful for correcting a psen1 point mutation within the genome of a cell or subject, e.g., within the human genome.
President And Fellows Of Harvard College


06/18/15
20150166982 

Methods for correcting pi3k point mutations


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a mutant pi3kca protein to correct a point mutation associated with a disease or disorder, e.g., with a neoplastic disorder. The methods provided are useful for correcting a pi3kca point mutation within the genome of a cell or subject, e.g., within the human genome.
President And Fellows Of Harvard College


06/18/15
20150166981 

Methods for nucleic acid editing


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of cas9 and nucleic acid editing enzymes or enzyme domains, e.g., deaminase domains, are provided.
President And Fellows Of Harvard College


06/18/15
20150166980 

Fusions of cas9 domains and nucleic acid-editing domains


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of cas9 and nucleic acid editing enzymes or enzyme domains, e.g., deaminase domains, are provided.
President And Fellows Of Harvard College


06/18/15
20150166678 

Compositions and methods comprising binding proteins for adalimumab


Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine tnf-α and was developed to treat tnf-α mediated inflammatory diseases.
Abbvie Biotechnology Ltd


06/18/15
20150166618 

Methods and compositions for treating hemophilia


Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins involved in clotting into the genome of a cell for treating conditions including hemophilias.. .
Sangamo Biosciences, Inc.


06/18/15
20150165054 

Methods for correcting caspase-9 point mutations


Some aspects of this disclosure provide strategies, systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a nucleic acid encoding a mutant caspase-9 protein to correct a point mutation associated with a disease or disorder, e.g., with neuroblastoma. The methods provided are useful for correcting a caspase-9 point mutation within the genome of a cell or subject, e.g., within the human genome.
President And Fellows Of Harvard College


06/18/15
20150164968 

Method of producing banana-derived composition and biologically active substance containing same


Provided is a method of producing a banana-derived composition by which a composition exhibiting excellent biological activity is obtained from a flesh part of a banana. The method includes the steps of (1) mincing a flesh part of a banana to obtain flesh fractions; (2) adding a proteolytic enzyme to the flesh fractions and decomposing proteins contained in the flesh fractions through an enzyme reaction, to obtain an enzymatic reactant; and (3) deactivating the proteolytic enzyme contained in the enzymatic reactant to obtain a composition a..

06/18/15
20150164956 

Muscle-derived cells (mdcs) for treating muscle- or bone-related injury or dysfunction


The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


06/18/15
20150164937 

Pharmaceutical or nutraceutical composition


The invention relates to a pharmaceutical or nutraceutical composition comprising an alkalized organic substance selected from the group comprising proteins, carbohydrates, lipids, amino acids, vitamins, therapeutic agents and mixtures thereof. Such compositions are useful for treating a range of diseases and conditions.

06/11/15
20150160204 

Methods of polypeptide identification, and compositions therefor


Methods are disclosed for identifying one or more proteins or polypeptides comprised by a sample. The methods comprise determining binding of each polypeptide with respect to each binding pool of a plurality of binding pools, wherein each binding pool comprises one or more probes which bind a structure comprised by a protein or polypeptide.
Washington University


06/11/15
20150160202 

Assays for affinity profiling of nucleic acid binding proteins


Methods, compositions and kits are disclosed for assays to determine the binding affinity of dna-binding proteins or rna-binding proteins for their corresponding recognition site(s). In particular, assays are disclosed for measuring binding affinities when either the binding protein, or the recognition sequence of the recognition site, or cofactor proteins, contain one or more mutations.
Affymetrix, Inc.


06/11/15
20150159172 

Methods and compositions for genome engineering


Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins that is aberrantly expressed in disease or disorder such as a lysosomal storage disease.. .
Sangamo Biosciences, Inc.


06/11/15
20150158922 

Transgenic plants expressing cobalamin binding proteins


The present invention relates to the use of transgenic plants for the expression of vitamin b12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin b12 binding proteins.
Xeragenx Llc


06/11/15
20150158920 

Transgenic plants expressing cobalamin binding proteins


The present invention relates to the use of transgenic plants for the expression of vitamin b12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin b12 binding proteins.
Xeragenx Llc


06/11/15
20150157731 

Transgenic plants expressing cobalamin binding proteins


The present invention relates to the use of transgenic plants for the expression of vitamin b12 (cobalamin) binding proteins. Plant cells are transformed with nucleotide sequences adapted for expression and secretion of vitamin b12 binding proteins.
Xeragenx Llc


06/04/15
20150152404 

Proteases producing an altered immunological response and methods of making and using the same


The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides dna molecules that encode novel variants, host cells comprising dna encoding novel variants, as well as methods for making proteins less allergenic.
Danisco Us Inc.


06/04/15
20150152194 

Dual receptor antagonistic antigen-binding proteins and uses thereof


This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. Antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases.
Amgen Inc.


06/04/15
20150150618 

System and creating radio-frequency energy electrical membrane breakdown for tissue ablation


A method of non-thermally ablating undesirable tissue in the body by application of pulsed, bi-polar, instant charge reversal electrical fields of sufficient energy to cause complete and immediate cell membrane rupture and destruction. Energy is delivered through radio frequency pulses of particular frequencies, wave characteristics, pulse widths and pulse numbers, such that enhanced physical stresses are placed on the cell membrane to cause its immediate and complete destruction thereby spilling the entire cell content and membrane constituents into the extracellular space without denaturing proteins so as to enable animmunological response to destroy and remove the target tissue and similarly marked tissue elsewhere in the subject..

06/04/15
20150150275 

Methods for processing acid whey


Methods for processing acid whey, involving treating acid whey solution with α-galactosidase and/or β-galactosidase, at a ph of about 3.2 to about 5.2 for about 20 minutes to about 16 hours at about 20° c. To about 60° c.
The United States Of America, As Represented By The Secretary Of Agriculture


05/28/15
20150148337 

Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof


The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders..
Constellation Pharmaceuticals, Inc.


05/28/15
20150148333 

Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof


The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders..
Contellation Pharmaceuticals, Inc.


05/28/15
20150147327 

Dual variable domain immunoglobulin and uses thereof


The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.. .
Abbvie Inc.


05/28/15
20150147323 

Modulating the alternative complement pathway


Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor h-binding proteins.. .
The Regents Of The University Of Colorado, A Body Corporate


05/28/15
20150147318 

Caninized anti-ngf antibodies and methods thereof


The invention provides novel caninized anti-ngf antibodies (such as caninized anti-ngf antagonist antibodies and antigen binding proteins), and polynucleotides encoding the same. The invention further provides use of said antibodies or antigen binding proteins and/or nucleotides in the treatment and/or prevention of ngf related disorders, particularly pain..
Zoetis Llc


05/21/15
20150143584 

Nucleic acid molecules encoding polypeptides involved in regulation of sugar and lipid metabolism and methods of use viii


This invention relates generally to nucleic acid sequences encoding proteins that are related to the presence of seed storage compounds in plants. More specifically, the present invention relates to arabidopsis thaliana, brassica napus, glycine max and oryza sativa nucleic acid sequences encoding sugar and lipid metabolism regulator proteins and the use of these sequences in transgenic plants.
Basf Plant Science Gmbh


05/21/15
20150140635 

Boronic and borinic acid compound as inhibitors of sulfenic acid-containing proteins


A boronic or borinic acid compound is used to inhibit the activity of a sulfenic acid-containing protein. Thus, a biologically-active sulfenic acid-containing protein is contacted with an activity-inhibiting effective amount of a boronic or borinic acid compound of formula i or a salt, hydrate or solvate thereof, whose components are disclosed within, and that contact is maintained for a time sufficient to inhibit the biological activity of the protein..

05/21/15
20150140580 

Antibodies to matrix metalloproteinase 9


The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), such as where the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.


05/21/15
20150139988 

Glycoengineered binding protein compositions


Provided are glycoengineered populations of fc domain-containing binding proteins with a reduced anti-drug immune response (ada). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions..
Abbvie, Inc.


05/14/15
20150133307 

Automated screening of enzyme variants


Disclosed are methods for identifying bio-molecules with desired properties (or which are most suitable for a round of directed evolution) from complex bio-molecule libraries or sets of such libraries. Some embodiments of the present disclosure provide methods for virtually screening proteins for beneficial properties.

05/07/15
20150126452 

Protein assembler


The present invention relates to a method for assembling (monomeric or oligomeric) proteins and peptide structures to multimeric protein or peptide structures. The present invention also provides a method for preparing peptide based polymers by crosslinking such multimeric proteins or peptides obtainable according to the inventive method and their use as polymers, for amphiphilic applications, as protein based detergents, for forming artificial organelles, etc.
Albert-luding-universitÄt Freiburg


05/07/15
20150126403 

Method of identifying proteins in human serum indicative of pathologies of human lung tissues


A method of identifying proteins present in human serum which are differentially expressed between normal individuals and patients known to have non-small cell lung cancers and asthma, as diagnosed by a physician. Human serum specimens from each population are digested with trypsin or any other suitable endoproteinase and analyzed using a liquid chromatography electrospray ionization mass spectrometer.
Cancer Prevention And Cure, Ltd


05/07/15
20150126402 

Method for quantifying proteins and isoforms thereof


A method for quantifying metallothionein protein isomers is described herein. Such metallothionein isomer protein quantification is useful for detecting and monitoring disease.
University Of North Dakota


05/07/15
20150125397 

Dual specific binding proteins directed against immune cell receptors and autoantigens


Engineered multivalent and multispecific binding proteins that bind immune cell receptors and/or autoantigens are provided, along with methods of making and uses in the prevention, diagnosis, prognosis and/or treatment of disease.. .
University Of Machusetts


04/30/15
20150119558 

Cho-gmt recombinant protein expression


The present invention provides modified cells for producing proteins with modified glycosylation patterns. Proteins produced in such cells, and the use of such proteins in medicine, and particularly in the treatment of cancer, is also provided..
Agency For Science, Technology And Research


04/30/15
20150118216 

Delivery of negatively charged proteins using cationic lipids


Compositions, methods, strategies, kits, and systems for the delivery of negatively charged proteins, protein complexes, and fusion proteins, using cationic polymers or lipids are provided. Delivery of proteins into cells can be effected in vivo, ex vivo, or in vitro.
President And Fellows Of Harvard College


04/23/15
20150111764 

Polymerized microarrays


Micropatterns of glycan-bearing brush polymers generated by the initiation of oligomerization of acrylate and methacrylate monomers from thiol-terminated surfaces. Chain lengths are controlled in situ by varying exposure time, and these multivalent glycan scaffolds detect glycan binding proteins at sub-micromolar concentrations..
New York University


04/23/15
20150111251 

Tnf-alpha binding proteins


Tnf-α binding proteins, including chimeric, cdr-grafted, and humanized antibodies that bind tnf-α are provided. Binding proteins have high affinity for tnf-α and neutralize tnf-α activity.
Abbvie Inc.


04/16/15
20150105285 

Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase


The present invention relates to a method for the production of a library comprising recombinant derivatives of the sh3 domain of the fyn kinase of seq id no: 1 as well as a method for selecting from a library comprising recombinant derivatives of the sh3 domain of the fyn kinase of seq id no: 1 one or more of said derivatives having a specific binding affinity to a protein or peptide.. .
Eidgenoessische Technische Hochschule Zurich


04/16/15
20150104468 

Site-specific labeling methods and molecules produced thereby


The present disclosure provides methods of site-specific labeling of antibodies, using proteins having 4′-phosphopantetheinyl transferase activity that catalyze post-translational modification of peptide sequences (“peptide tags”) incorporated into one or more specific sites of an antibody of interest. Enzymatic labeling enables quantitative and irreversible covalent modification of a specific serine residue within the peptide tags incorporated into the antibody, and thus creates desirable antibody conjugates..
Irm Llc


04/16/15
20150104452 

Dual variable domain immunoglobulins and uses thereof


The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie Inc.


04/09/15
20150099290 

Insertion of charge in the hydrophobic interior of proteins as a strategy for engineering ph-sensitive switches


Methods are provided for engineering non-naturally occurring proteins comprising artificial ph-sensitive conformational switches that respond to a change in ph by causing a global unfolding of the proteins. Non-naturally occurring proteins comprising artificial ph-sensitive conformational switches that respond to a change in ph by causing a global unfolding of the proteins are also provided..
The Johns Hopkins University


04/09/15
20150098950 

Liquid formulations of tumor necrosis factor-binding proteins


The invention relates to a stable, pharmaceutically acceptable, aqueous formulation of tnf-binding protein, comprising a tnf-binding protein, a buffer and an isotonicity agent.. .
Ares Trading S.a.


04/02/15
20150094453 

Isolated egg protein and egg lipid materials, and methods for producing the same


A method for separating proteins and fats from an egg mixture is disclosed herein. The method includes a step of microfiltration of the egg mixture, wherein microfiltration includes pumping across a filter an egg mixture containing egg yolk and egg whites (albumen).
Rembrandt Enterprises, Inc.


04/02/15
20150093387 

Dual variable domain immunoglobulins and uses thereof


The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
Abbvie, Inc.


03/26/15
20150089680 

Human lambda light chain mice


Genetically modified mice are provided that express human λ variable (hvλ) sequences, including mice that express hvλ sequences from an endogenous mouse λ light chain locus, mice that express hvλ sequences from an endogenous mouse κ light chain locus, and mice that express hvλ sequences from a transgene or an episome wherein the hvλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins.
Regeneron Pharmaceuticals, Inc.


03/26/15
20150087819 

Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)


Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
Amgen Inc.


03/26/15
20150087532 

Affinity reagents for protein purification


Disclosed herein are methods and compositions for purifying proteins from crude solutions.. .
The Board Of Trustees Of The Leland Stanford Junior University


03/26/15
20150086636 

Myostatin inhibition for enhancing muscle and/or improving muscle function


The present invention relates to methods for inhibiting myostatin, a regulator of muscle mass, for muscle enhancement (including inducing hypertrophy and/or hyperplasia) as well as improving muscle function (including decreasing atrophy and/or increasing endurance, force and/or strength). Some of the methods involve delivering genes to cells using gene delivery or other delivery techniques known in the art in order to inhibit myostatin.
Nationwide Children's Hospital


03/26/15
20150086563 

Alpha-4-beta-7 heterodimer specific antagonist antibody


There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.. .
Amgen Inc.


03/26/15
20150086556 

Anti-activin a antibodies and uses thereof


The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
Amgen Inc.


03/26/15
20150086554 

Dual variable domain immunoglobulin and uses thereof


The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.. .
Abbvie Inc.


03/19/15
20150080558 

Chromatography matrices including novel staphylococcus aureus protein a based ligands


The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, staphylococcus aureus protein a (spa), as well as methods of using the same.. .
Emd Millipore Corporation


03/19/15
20150080248 

Methods for isolating proteins


The invention generally relates to methods for isolating proteins. In certain aspects, methods of the invention involve preparing a plurality of sample preparations, each preparation including one or more intact cells.
Purdue Research Foundation


03/19/15
20150079062 

Method for harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment


The invention provides a method of harvesting, processing and storing a plurality of proteins from a mammalian feto-placental unit. The method includes dissecting a mammalian uterus to harvest at least one component of the mammalian feto-placental unit; blast freezing the component; and storing the blast frozen component; wherein the blast frozen component includes the proteins.

03/19/15
20150079061 

Method for the harvesting, processing, and storage of proteins from the mammalian feto-placental unit and use of such proteins in compositions and medical treatment


The invention provides a method of harvesting, processing and storing a plurality of proteins from a mammalian feto-placental unit. The method includes dissecting a mammalian uterus to harvest at least one component of the mammalian feto-placental unit; blast freezing the component; and storing the blast frozen component; wherein the blast frozen component includes the proteins.

03/19/15
20150079038 

Selective recovery


Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided..
California Institute Of Technology


03/12/15
20150074852 

Genetic loci associated with head smut resistance in maize


Head smut is one of the most devastating diseases in maize, causing severe yield loss worldwide. The present invention describes the fine-mapping of a major qtl conferring resistance to head smut.
E I Du Pont De Nemours And Company


03/12/15
20150074836 

Mutations of the parkin gene, compositions, methods and uses


The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes..
Institut National De La Santé Et De La Recherche Médicale


03/12/15
20150072937 

Chimeric peptides for the regulation of gtpases


Chimeric peptides or fusion proteins are disclosed that include a rhogap activity domain and at least one specificity domain that targets a specific rho protein. The fusion proteins can be used to inhibit any gtpase activity within a cell.
Children's Medical Center Corporation


03/12/15
20150072412 

Identification of antigen or ligand-specific binding proteins


The present invention discloses novel methods for the generation, expression and screening of diverse collections of binding proteins such as antibodies or fragments thereof in vertebrate host cells in vitro, for the identification and isolation of ligand- or antigen-specific binding proteins. The methods disclosed herein allow the expression of diverse collections of binding proteins from at least one vector construct, which optionally can give rise to collections of diverse binding proteins upon transfer and expression into vertebrate host cells in situ..
4-antibody Ag


03/05/15
20150067921 

Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks


A method of gene editing or gene stacking within a fad3 loci by cleaving, in a site directed manner, a location in a fad3 gene in a cell, to generate a break in the fad3 gene and then ligating into the break a nucleic acid molecule associated with one or more traits of interest is disclosed.. .
Dow Agrosciences Llc


03/05/15
20150065440 

Sulfated oligosaccharide derivatives


The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.. .
Progen Pharmaceuticals Limited


03/05/15
20150065378 

Synthetic oligonucleotides for detection of nucleic acid binding proteins


Synthetic oligonucleotides that comprise a nucleic acid binding protein binding site, pcr primer sequences, and tag sequences that do not bind to nucleic acid binding proteins, with a total length of 85-130 nucleotides are disclosed herein. Also disclosed are libraries and kits comprising the synthetic oligonucleotides as well as methods of detecting nucleic acid binding proteins in a sample using the synthetic oligonucleotides..
Oregon Health & Science University


03/05/15
20150064766 

Beta-glucosidase variants


The invention relates to recombinantly produced β-glucosidase variants with enhanced thermoactivity compared to naturally occurring proteins. The invention also provides methods for producing a variant β-glucosidase polypeptide with improved thermoactivity by identifying performance sensitive positions in a target β-glucosidase polypeptide and substituting the residue at that position with a thermoactivity enhancing residue..
Codexis, Inc.


03/05/15
20150064744 

Modified enterokinase light chain


The present invention is related to novel mammalian enterokinase analogues such as mammalian enterokinase light chain analogues and methods of making such. Also described herein is a method for cleaving proteins having an enterokinase cleavage site..
Novo Nordisk A/s


03/05/15
20150064688 

Method of making a microfluidic device


A microfluidic device allowing for multiple discrete reactions sites and allowing for sequential reactions and sample analysis along with methods for device fabrication and use is provided. The microfluidic device provides a micro-total analysis system on a single substrate and has multiple reaction sites allowing for cascade reactions and analysis on a single chip using micro-quantities of sample and reagents.
National Science And Technology Development Agency


03/05/15
20150064211 

Synthetic active peptide fragments


The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kda protein of s. Mansoni (sm14) or related fabps (fatty acid binding proteins), the peptide fragments functioning as continuous or discontinuous epitopic regions of the molecule or mimicking its biological activity.
FundaÇao Oswaldo Cruz - Fiocruz


03/05/15
20150064204 

Gitr antigen binding proteins


Antigen binding proteins that activate gitr are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided.
Amgen Inc.


03/05/15
20150064201 

Antigen binding proteins to oncostatin m (osm)


The present invention concerns antigen binding proteins and fragments thereof which specifically bind oncostatin m (osm), particularly human osm (hosm) and which inhibit the binding of osm to the gp130 receptor but does not directly interact with site ii residues. The invention also concerns a method of humanising antibodies.
Glaxo Group Limited


02/26/15
20150059009 

Methods for making fully human bispecific antibodies using a common light chain


A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline.
Regeneron Pharmaceuticals, Inc.


02/26/15
20150057243 

Compositions and methods for the inhibition of methyltransferases


Methods and compositions disclosed herein relate to detecting, analyzing, isolating and inhibiting methyltransferases, methyltransferase substrates, s-adenosyl-methionine-binding proteins and rna, including for the treatment of disease.. .
Northern University


02/26/15
20150056680 

Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses


The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor.
Ibc Pharmaceuticals, Inc.


02/26/15
20150056634 

Methods for preparing dry formulations of glucose binding protein


Methods and compositions for preparing dry formulations of glucose binding proteins (gbps) are disclosed. The gbps may be stored as a dry formulation without significant loss of activity.
Becton, Dickinson And Company


02/26/15
20150056211 

Heparin-binding epidermal growth factor-like growth factor binding proteins


Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (hb-egf) and neutralize the biological functions of this growth factor.. .
Amgen, Inc.


02/26/15
20150056202 

Anti-tnf/il-17 dual variable domain immunoglobulin and uses thereof


The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.. .
Abbvie, Inc.




Popular terms: [SEARCH]

G Proteins topics: G Proteins, Antibodies, Immunoglobulin, Metalloprotein, Chemotherapeutic Agent, Kinase Inhibitor, Tetrapeptide, Apoptosis Protein, Topoisomerase, Peptidomimetic, Fractionation, Medical Treatment, Chromatograph, Encapsulation, Electrospraying

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to G Proteins for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Proteins with additional patents listed. Browse our RSS directory or Search for other possible listings.


4.7763

4900

0 - 1 - 106